siRNA theraputic - Medesis Pharma
Alternative Names: NanosiRNA® COVID-19; NanosiRNA® COVID-19 - Medesis PharmaLatest Information Update: 28 Apr 2024
At a glance
- Originator Medesis Pharma SA
- Class Antivirals; Small interfering RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in COVID-2019-infections in France (Buccal, Liquid)
- 01 Apr 2021 siRNA therapeutic is available for licensing as of 01 Apr 2021. https://www.medesispharma.com/corporate/vision/
- 01 Apr 2021 Medesis Pharma has patent protection for AONYS® in Australia, Canada, China, Eurasia, Hong Kong, India, Israel, Japan, South Africa, USA (Medesis Pharma website, March 2021)